Sibban Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 133.72%
- Ebitda -335.37%
- Net Worth -219.48%
- Total Assets 244.22%
About Sibban Pharma
Sibban Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 August 2020 (Four years and six months 11 days old ). Its registered office is in Gautam Buddha Nagar, Uttar Pradesh, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Kumar, Pradeep Vidhuri, and Akash Bhati serve as directors at the Company.
Company Details
-
Location
Gautam Buddha Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2020PTC132229
-
Company No.
132229
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Aug 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Sibban Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar
|
Director | 05-Aug-2020 | Current |
|
Pradeep Vidhuri
|
Director | 05-Aug-2020 | Current |
|
Akash Bhati
|
Director | 08-Sep-2022 | Current |
Financial Performance of Sibban Pharma.
Sibban Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 133.72% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 219.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sibban Pharma?
Unlock access to Sibban Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Dr. Nurture Pharmaceutical Private LimitedAnil Kumar is a mutual person
-
Star Eleven Hospitality Private Limited
Anil Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sibban Pharma?
Unlock and access historical data on people associated with Sibban Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sibban Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sibban Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.